Skip to main content

Is Market Sentiment Getting Behind This Emerging Small-Cap Specialty Syringe Medical Device Company?

By David Willey, Benzinga

The medical device and supply manufacturing industry is focused on the design and production of medical instruments and devices. As innovation and demand for medical devices increase, the market for this industry, which is currently worth approximately $99 billion, is very likely to grow. However, it looks like the rising tide isn’t lifting all boats equally. It has been reported that the market is rallying behind some leaders in the industry, but not others. One of the reported rising companies is Sharps Technology (NASDAQ: STSS).

A specialty syringe developer and manufacturer which has a market cap of just $15 million, Sharps is a company in the space that seems to be poised for growth and is receiving positive investor sentiment. The specialty medical device company recently received a bullish sentiment stock reading from investing group InvestorsObserver.

At the same time, a number of other medical device companies have seemingly received underperforming commentary or are within the feeling of market uncertainty and hesitancy, such as Becton Dickson and Co. (NYSE: BDX), Cardinal Health (NYSE: CAH), and Terumo Corporation (OTC: TRUMY).

Why is it that some medical device companies such as Sharps seem to have the support of market traders, while others don’t? There may be several contributing reasons.

Investment Groups are Giving Sharps Technology a Positive Outlook

The forum scoreboard on shows Sharps Technology as having a 100% bullish sentiment rating from the forum’s users. Some traders on Stocktwits have also labeled Sharps’ stock as bullish. One trader cited the reduced capital needed to manufacture, as well as the reduced liability that comes with Sharps’ products, as reasons the company is well positioned in the market. Sharps has a wholly-owned 40K sq. ft manufacturing facility in Hungary with potential capacity of up to 200 million disposable syringe units in 2024, and through its collaboration with Nephron Pharmaceuticals (private), has potential capacity of up to 50 million units of prefillable syringe systems in South Carolina.

Retail investment outlet Simply Wall Street highlighted Sharps as having high growth potential, suggesting that the stock currently trades at 98% below its estimate of fair value. Meanwhile, another investment consultant praised the company for its manufacturing capacity capabilities. Manufacturing scalability potential, along with synergies through the partnership with Nephron, were mentioned as having strong potential to lead to growth in topline revenue.

A couple of recent announcements from Sharps may have also contributed to this seemingly bullish market sentiment. Sharps recently announced two significant progress updates with a press release on plans to introduce new specialized prefillable syringe systems in 2023, as well as shipping the first containers of syringes from its Hungary facility for commercialization.

Interested in learning more about Sharps Technology? Visit its website.

This article was originally published on Benzinga here.

Sharps Technology is a medical device and pharmaceutical packaging company specializing in the development and manufacturing of innovative drug delivery systems. The company’s product lines focus on low waste and ultra-low waste syringe technologies that incorporate both passive and active safety features. These features protect front line healthcare workers from life-threatening needle stick injuries and protect the public from needle re-use. Sharps Technology has extensive expertise in specialized prefilled syringe systems and ready to use processing. The company has a manufacturing facility in Hungary and has partnered with Nephron Pharmaceuticals to expand its manufacturing capacity in the US.

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Contact Details

Adam Holdsworth- TraDigital IR

Company Website

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.